drugset / Trial / NCT03520946
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Phase 3
Completed
430 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Eli Lilly and Company · collabTrium Analysis Online GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and tolerability.
Timeline
- Start
- 2019-01-24
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | Oral |